Bootstrapping
fromEntrepreneur
20 hours agoEquity Feels Safe. Debt Feels Risky. Reality Says Otherwise.
Debt-based financing promotes strong fundamentals, while equity can obscure inefficiencies and escalate expectations for growth.
The iShares Biotechnology ETF is the default large-cap vehicle for the sector. It is market-cap weighted, which concentrates the fund in cash-generative incumbents rather than spreading capital across clinical-stage names.
Tim Cook described John Ternus as 'a brilliant engineer and thinker who has spent the past 25 years building the Apple products our users love so much, obsessed with every detail, focused on every possible way we can make something better, bolder, more beautiful, and more meaningful.'
The ETF itself is a bond fund that tracks a market of investment-grade U.S. agency mortgage-backed securities, meaning pools of home loans packaged into bonds and issued or guaranteed by Fannie Mae, Freddie Mac, and Ginnie Mae.
The Value ETF tracks the CRSP US Large Cap Value Index, focusing on large-capitalization value stocks. It holds positions in a diversified set of companies, with recent data indicating around 312 stocks in total. Rather than the large tech stocks found propping up the portfolios of other ETFs, such as the Vanguard S&P 500 ETF or the Vanguard Total Stock Market ETF, its largest positions emphasize traditional value sectors rather than high-growth momentum.
The Invesco DB Commodity Index Tracking Fund (NYSEARCA:DBC) is up 42% over the past year, and nearly 29% year-to-date. These gains reflect a war that has scrambled global commodity supply chains from crude oil to wheat to fertilizer.
At lower portfolio sizes, income investing feels like something of a compromise. A 4% yield on $200,000 gives you $8,000 a year, which is barely $667 a month, so it's supplemental income at best. However, jump up to $500,000, even a moderate 5% blended yield can produce $25,000 a year, or right around $2,080 monthly.